IMGN ImmunoGen Inc

Price (delayed)

$6.69

Market cap

$1.34B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.25

Enterprise value

$1.08B

Highlights
IMGN's EPS has soared by 56% year-on-year
The company's revenue has surged by 55% YoY
The net income has increased by 45% YoY but it has decreased by 11% from the previous quarter
IMGN's quick ratio is down by 26% year-on-year and by 13% since the previous quarter

Key stats

What are the main financial stats of IMGN
Market
Shares outstanding
199.94M
Market cap
$1.34B
Enterprise value
$1.08B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
14.2
Price to sales (P/S)
9.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
Earnings
Revenue
$134.72M
EBIT
-$49.24M
EBITDA
-$47.12M
Free cash flow
-$96.72M
Per share
EPS
-$0.25
Free cash flow per share
-$0.49
Book value per share
$0.47
Revenue per share
$0.68
TBVPS
$1.74
Balance sheet
Total assets
$345.96M
Total liabilities
$251.84M
Debt
$23.09M
Equity
$94.12M
Working capital
$185.22M
Liquidity
Debt to equity
0.25
Current ratio
2.38
Quick ratio
2.26
Net debt/EBITDA
5.52
Margins
EBITDA margin
-35%
Gross margin
100%
Net margin
-36.6%
Operating margin
-20.4%
Efficiency
Return on assets
-16.2%
Return on equity
-169.7%
Return on invested capital
N/A
Return on capital employed
-23.3%
Return on sales
-36.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMGN stock price

How has the ImmunoGen stock price performed over time
Intraday
0.15%
1 week
3.24%
1 month
-1.62%
1 year
46.71%
YTD
3.72%
QTD
-17.41%

Financial performance

How have ImmunoGen's revenue and profit performed over time
Revenue
$134.72M
Gross profit
$134.72M
Operating income
-$27.49M
Net income
-$49.34M
Gross margin
100%
Net margin
-36.6%
The operating margin has soared by 76% year-on-year but it is down by 21% since the previous quarter
ImmunoGen's net margin has surged by 64% YoY but it has decreased by 9% QoQ
The company's operating income has surged by 63% YoY but it fell by 23% QoQ
The company's revenue has surged by 55% YoY

Growth

What is ImmunoGen's growth rate over time

Valuation

What is ImmunoGen stock price valuation
P/E
N/A
P/B
14.2
P/S
9.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
IMGN's EPS has soared by 56% year-on-year
The equity has grown by 5% from the previous quarter
The company's revenue has surged by 55% YoY
The price to sales (P/S) is 13% higher than the 5-year quarterly average of 8.7 and 7% higher than the last 4 quarters average of 9.2

Efficiency

How efficient is ImmunoGen business performance
IMGN's ROE has soared by 83% from the previous quarter
IMGN's ROS has soared by 64% year-on-year but it is down by 9% since the previous quarter
The ROA has soared by 51% YoY but it has contracted by 7% from the previous quarter

Dividends

What is IMGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMGN.

Financial health

How did ImmunoGen financials performed over time
ImmunoGen's total assets is 37% higher than its total liabilities
IMGN's quick ratio is down by 26% year-on-year and by 13% since the previous quarter
ImmunoGen's current ratio has decreased by 25% YoY and by 10% from the previous quarter
ImmunoGen's debt is 75% lower than its equity
IMGN's debt to equity has surged by 104% year-on-year but it is down by 7% since the previous quarter
ImmunoGen's debt has decreased by 12% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.